CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Salk Institute for Biological Studies |
Juan Carlos Izpisua Belmonte |
Training Grant I-3 |
Training in the Biology of Human Enbryonic Stem Cells and Emerging Technologies |
$1,261,333 |
| California Institute of Technology |
Paul H. Patterson |
Training Grant I-2 |
Training in Stem Cell Biology at CIT |
$1,817,214 |
| Children’s Hospital of Los Angeles |
Dr. Donald B. Kohn |
Training Grant I-2 |
Training Grant 1 |
$2,173,872 |
| Sanford Burnham Prebys Medical Discovery Institute |
Mark Mercola |
Training Grant I-2 |
Burnham Institute CIRM Stem Cell Training Grant (Type II) |
$1,061,865 |
| Gladstone Institutes, J. David |
Dr. Robert W Mahley |
Training Grant I-2 |
Gladstone CIRM Scholar Program |
$2,192,073 |
| Scripps Research Institute |
Peter G. Schultz |
Training Grant I-2 |
Training Grant I |
$1,021,395 |
| University of California, Davis |
Dr. Frederick J Meyers MD |
Training Grant I-1 |
Stem Cell Research Training Grant |
$1,780,859 |
| University of California, San Francisco |
Dr. Susan J Fisher PhD |
Training Grant I-1 |
Training Grant I |
$2,868,145 |
| University of California, Los Angeles |
Dr. Owen N Witte M.D. |
Training Grant I-1 |
CIRM Type I Comprehensive Training Program |
$3,660,398 |
| University of Southern California |
Dr. Robert E Maxson |
Training Grant I-1 |
CIRM Stem Cell Biology Training Grant |
$2,332,431 |
| University of California, Irvine |
Dr. Peter Bryant |
Training Grant I-1 |
Stem Cell Research Training Grant |
$1,935,487 |
| University of California, Berkeley |
Randy W. Schekman |
Training Grant I-1 |
Human Stem Cell Training at UC Berkeley and Childrens Hospital of Oakland |
$2,360,457 |
| University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Training Grant I-1 |
Interdisciplinary Stem Cell Training Program at UCSD |
$3,459,396 |
| Stanford University |
Dr Michael T Longaker |
Training Grant I-1 |
Stanford CIRM Training Program |
$3,035,282 |
| University of California, Davis |
Mehrdad Abedi |
Disease Team Therapy Planning I |
Stem Cell Gene Therapy for HIV in AIDS Lymphoma Patients |
$66,880 |
| University of California, Davis |
Dr. John Laird |
Disease Team Therapy Planning I |
Phase I study of IM Injection of VEGF Producing MSC for the Treatment of Critical Limb Ischemia |
$76,066 |
| University of California, Davis |
Dr. Vicki Wheelock |
Disease Team Therapy Planning I |
MSC engineered to produce BDNF for the treatment of Huntington’s disease |
$97,564 |
| Cedars-Sinai Medical Center |
Professor Clive Niels Svendsen |
Disease Team Therapy Planning I |
Stem Cells Secreting GDNF for the Treatment of ALS |
$63,487 |
| Stanford University |
Dr. Albert J Wong |
Disease Team Therapy Planning I |
Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma |
$109,750 |
| Stanford University |
Dr. Judith A Shizuru |
Disease Team Therapy Planning I |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$90,147 |
| OncoMed Pharmaceuticals, Inc. |
Timothy Hoey |
Disease Team Therapy Planning I |
Anti-Notch1, OMP-52M51: A New Cancer Therapeutic to Reduce CSC Frequency |
$65,120 |
| Cedars-Sinai Medical Center |
Dr. Dan Gazit |
Disease Team Therapy Planning I |
Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures. |
$107,622 |
| StemCells, Inc. |
Dr. Alexandra Capela |
Disease Team Therapy Planning I |
Neuroprotection to treat Alzheimer’s: a new paradigm using human central nervous system cells |
$90,101 |
| University of California, Los Angeles |
Dr. Stanley Nelson |
Disease Team Therapy Planning I |
Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$68,947 |
| Geron Corporation |
Dr. Jane Stephanie Lebkowski Dr. |
Disease Team Therapy Planning I |
Preclinical Development and First-In-Human Testing of GRNCM1 in Advanced Heart Failure |
$0 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Marcel Daadi Dr. |
Disease Team Therapy Planning I |
Neural Stem Cell-Based Therapy For Parkinson’s Disease |
$63,952 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Stuart A Lipton |
Disease Team Therapy Planning I |
hESC-derived NPCs Programmed with MEF2C for Cell Transplantation in Parkinson’s Disease |
$96,448 |
| University of California, Davis |
Nancy E. Lane |
Disease Team Therapy Planning I |
Increasing the endogenous mesenchymal stem cells to the bone surface to treat osteoporosis |
$107,750 |
| University of Southern California |
Roberta Diaz Brinton |
Disease Team Therapy Planning I |
A CIRM Disease Team to Develop Allopregnanolone for Prevention and Treatment of Alzheimer’s Disease |
$107,961 |
| Samumed, LLC |
John Hood |
Disease Team Therapy Planning I |
Clinical Development of an osteoinductive therapy to prevent osteoporosis-related fractures |
$99,110 |
| Stanford University |
Dr. Robert Robbins |
Disease Team Therapy Planning I |
Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$73,030 |
| University of California, Davis |
Dr. Martin Birchall |
Disease Team Therapy Planning I |
Airways for Children |
$19,800 |
| University of California, Los Angeles |
Dr. Antoni Ribas MD/PhD |
Disease Team Therapy Planning I |
Genetic Re-programming of Stem Cells to Fight Cancer |
$97,785 |
| California State University San Marcos Corporation |
Dr. Bianca Romina Mothé |
Bridges |
California State University-San Marcos CIRM Bridges to the Stem Cell Research Training Grant |
$4,114,712 |
| Cal State Univ, Long Beach |
Dr. Lisa S Klig |
Bridges |
CIRM Stem Cell Research Biotechnology Training Program at CSULB |
$3,487,091 |
| Cal Poly Pomona Foundation |
Dr. Jill Adler-Moore |
Bridges |
Cal Poly Pomona and Cal State LA Collaborative CIRM Bridges Program to Enhance Stem Cell Research Training and Education |
$3,056,191 |
| San Francisco State University |
Dr. Carmen Domingo |
Bridges |
SFSU Bridges to Stem Cell Research |
$4,168,243 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent
Cardiovascular Events |
$12,714,480 |
| 4D Molecular Therapeutics, Inc. |
Sara Collins |
Preclinical Stage Projects |
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency |
$5,915,073 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Preclinical Stage Projects |
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies |
$7,500,000 |
| Cure Rare Disease |
Dr. Tahseen Mozaffar |
Preclinical Stage Projects |
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 |
$7,292,297 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia |
$13,000,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Preclinical Stage Projects |
Microglia replacement therapy for CSF1R-related Leukoencephalopathy |
$12,993,456 |
| Cedars-Sinai Medical Center |
Dr. David Joseph Lefer |
Preclinical Stage Projects |
TY1 and Semaglutide to Treat Cardiometabolic HFpEF |
$10,571,220 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Preclinical Stage Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$7,423,504 |
| Cedars-Sinai Medical Center |
Dr. Alessandra Ciullo |
Preclinical Stage Projects |
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy |
$10,419,929 |
| Navega Therapeutics |
Ana Maria Moreno |
Preclinical Stage Projects |
Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders |
$9,486,864 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Stage Projects |
Stem Cell-Based Cartilage Tissue Regeneration |
$12,715,000 |
| Stanford University |
Dr. Bertha Chen |
Preclinical Stage Projects |
Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence |
$7,275,596 |
| Loma Linda University |
Hisham Abdel-Azim |
CCCE Grant |
Inland Empire and Desert Region CIRM Community Care Center of Excellence |
$9,000,000 |
